top of page

Cambridge, UK based LoQus23 Therapeutics will use a small molecule allosteric inhibitor of MutSβ to treat Huntington's

  • blonca9
  • Jan 29, 2025
  • 1 min read

Co-Founder and CEO David Reynolds describes why LoQus23 is taking a small molecule approach to neurodegenerative diseases and why they believe stopping DNA instability is the right approach to Huntington's and other conditions.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page